The Users Group remains concerned, however, that the MCA has still not agreed to consider the personal experiences of Seroxat users in the review of the drug. Sarah Venn said: “We have offered to provide the MCA with all the information we have gathered about adverse reactions, dependence and withdrawal reactions, but they have not decided how or even if they will include patients’ experiences in the review. That is extremely worrying and we will continue to press them on this important point.”
http://webcache.googleusercontent.com/search?q=cache:YNIwlocOuhQJ:www.seroxatusergroup.org.uk/Documents/jw0328%2520ssri%2520review%2520panel%2520dissolved.doc+goodrelations+seroxatusergroup&cd=10&hl=en&ct=clnk&gl=uk&client=firefox-a
Seroxat is also known as Paxil and Aropax. Blog exposes Bob Fiddaman Human rights abuser who won two SCIENTOLOGY CCHR (human rights!) awards.
blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1
This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1
Tuesday, 19 October 2010
Monday, 18 October 2010
Seroxat counterpoint blog
This counterpoint blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1
Is the Seroxat Group Action Litigation Order no: 68 Compromised by its Own Defining Issue?
The UK Seroxat Group Action Litigation, Order No:68, is being brought under the Consumer Protection Act 1987 (CPA)
http://the-uk-seroxat-litigation-chronicles.blogspot.com/2010/10/is-seroxat-group-action-litigation.html
HM Courts Service: Seroxat Group Litigation Order no: 68.
The report of the Committee on Safety of Medicines (CSM), Expert Working Group (EWG) on SSRI Antidepressants, published December 2004, found all drugs in the class lacking in safety, efficacy and causing discontinuation problems in up to 80% of consumers.
It’s unclear why the “stipulation” has been included, as The CSM Expert Working Group report on all SSRI Antidepressants effectively proved the Group Action litigants case against GSK by finding their product Seroxat not being as "safe as persons generally are entitled to expect,".
December 2004, Seroxat Group Action Litigation case proved and won -
baring lead lawyer Mark Harvey’s inclusion of the apparently unnecessary and possibly untenable Defining Issue “stipulation”.
To prove the Seroxat Group Action by justifying the included “stipulation” raises the need to examine criteria that differentiate the drugs in the SSRI, SNRI class within the restricted Defining Issue of discontinuation, withdrawal and drug classification.
This depends on the two theories of what causes discontinuation and withdrawal and the issues of selectivity nature, affinity and potency; dose related drug action classification; definition by acronym classification; and external evidence.
All interrelate, and other than the issue of selectivity nature, affinity and potency, focus on two drugs in the class the SSRI paroxetine (Seroxat) and SNRI venlafaxine (Wyeth, Efexor UK, Effexor USA).
The CSM EWG into SSRI Antidepressants used pharmacological characteristics and the 1999 Tatsumi et al study to compare Half-life and the Potency and Affinity of the drugs on the central nervous system neurotransmitters. Finding all drugs have binding affinities to different monoamine transporters, primary effects on different receptors and cause secondary changes in receptor numbers and receptor function at the synapse.
1 - The issue of selectivity nature, affinity and potency is the most complicated – defining whether Seroxat is worse than any other drug in the class by comparing drugs with different intrinsic values that despite their acronym name classification titles i.e. SSRI, SNRI etc - are not “pharmacologically “clean”” or defined in action of selectivity “to the Serotonin system”, all also affecting to varying degrees noradrenalin and dopamine. This aspect is covered in more detail here.
The Tatsumi et al study results are valued using Kd or dissociated constant – as explained on the table the lower the Kd the higher the affinity to the transporter.
Affinity Kd ratings show –
Paroxetine (Seroxat) has the highest affinity to Serotonin at 0.1 - just point 0.2 higher that Sertraline (Pfizer, Lustral UK, Zoloft USA) the second highest at 0.3.
Potency findings published by CSM, EWG are not clear because they have not stated whether they are rating Potency on the Affinity to Serotonin alone or Serotonin (5HT), Noradrenalin (NA) and dopamine (DA).
Potency rating show –
Paroxetine (Seroxat) is the “most potent” with the “lowest selectivity” and Sertraline (Lustral) the “second most potent”.
However, when comparing the Affinity and Potency with other drugs in the class - that all to varying degrees effect 5HT, NA and DA and as Paroxetine (Seroxat) is the least selective and only has a negligible 0.2 higher Affinity to Serotonin than Sertraline (Lustral), total Affinity and Potency Kd values to 5HT, NA and DA could be used to assess this point.
Combined Kd Affinity and Potency values to Serotonin (5HT), Noradrenalin (NA) and Dopamine (DA) show –
Sertraline (Lustral) has the highest combined Affinity and Potency with a Kd 445.3 and the least selective Paroxetine (Seroxat) is second highest with a combined Kd of 530.1.
2 - The two theories of what causes discontinuation and withdrawal is explained by Dr David Healy in the “HALTING SSRIs” document, one theory is the shorter half-life of paroxetine (Seroxat) and venlafaxine (Efexor) makes these drugs more problematic, the second theory is regarding the potency of paroxetine and venlafaxine. This aspect is covered in more detail here.
If according to the first theory - which includes a switch to fluoxetine (Ely Lilly Prozac UK and USA) Half-life 1 to 4 days - the cause of discontinuation and withdrawal is dependant on the shortness of Half-life - venlafaxine (Efexor) has the shortest Half-life of 5 hours - paroxetine (Seroxat) is considerably longer at 20 hours.
The second theory - which includes a switch to citalopram (Lundbeck, Cipramil, Celexa) Kd 1.2 - with regard paroxetine (Seroxat) and venlafaxine (Efexor) being “relatively more potent serotonin reuptake inhibitors” is possibly itself called into question by the findings of the CSM, EWG and Tatsumi et al study as venlafaxine has a Kd value of 152 making it, other than mirtazapine, the least “potent serotonin reuptake inhibitor” of the drugs studied.
This possibly places the whole onus of discontinuation and withdrawal problems inherent with all drugs in the SSRI, SNRI class back on a drugs Half-life as citalopram’s Half-life at 36 hours, is longer than both paroxetine (Seroxat) and venlafaxine (Efexor) – and would possibly benefit some as with the fluoxetine switch.
3 - The dose related drug action classification issue, Wyeth are the only manufacturer of those drugs studied to have specified that their drug works on more than one neurotransmitter, however it is the opinion of Dr David Healy in the “HALTING SSRIs” document and the MHRA that although Venlafaxine is named by the acronym SNRI it’s mode of action is that of an SSRI up to doses of 150 mg, over this it has an additional mode of action to become a serotonin and noradrenalin reuptake inhibitor. This aspect is covered in more detail here
4 - The drug definition by acronym classification title by definition the difference between an SSRI and an SNRI should be dependant on selectivity and potency of action i.e. to serotonin or noradrenalin. In the case of the SSRI, SNRI drug class no drug is “selective” to one monoamine transporter, all drugs effect serotonin and noradrenalin, paroxetine (Seroxat) with Kd of 40 to the noradrenalin transporter has a considerably higher affinity than venlafaxine at a NA of Kd 9400. This aspect is covered in more detail here.
5 - The issue of external evidence, as covered briefly here, is dependant on the MHRA, Yellow Card Scheme adverse drug reports and media coverage that has influenced those reports. The MHRA has received considerably more adverse event reports for paroxetine (Seroxat) than any other drug in the class, however, the December 2004 CSM). EWG Report drew attention to the influence of the media coverage and a number of obviously duplicated reports made with regard paroxetine (Seroxat) and it has been noted that BBC Panorama published and issued it’s own Yellow Cards that were accepted by the MHRA.
I will return to the influence of media coverage, the BBC, Panorama, UK Government officials and departments, the Seroxat User Group.org and Hugh James Solicitors in more depth in future posts - but the media coverage has had a profound influence on this aspect, as the Richard M Martin, Margaret May, and David Gunnell, Department of Social Medicine, University of Bristol study “Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001–2004” shows.
Is the UK Seroxat Group Action Litigation, Order No:68 compromised by Lead Lawyer of Hugh James, Cardiff, Mark Harvey’s included Defining Issue “stipulation”?
1 - Does an Affinity and Potency to serotonin of Kd 0.2 higher than Sertraline (Lustral) make Paroxetine (Seroxat) the worst drug in the class …. or does the highest combined Affinity and Potency Kd to serotonin, noradrenalin and dopamine make Sertraline (Lustral) a worse drug than the least selective Paroxetine (Seroxat)?
2 - If the theory is that discontinuation and withdrawal is caused by the drugs short Half-life …. does SNRI venlafaxine’s (Efexor) half-life of 5 hours make it more difficult to withdraw from than the SSRI Paroxetine’s (Seroxat)?In proving a case of a “defective product” the only need is to show the product – in this case GlaxoSmithKline’s (GSK) drug Seroxat (Seroxat UK, Paxil USA) - was not up to consumers’ expectations.
3 - Is Wyeth’s honest mode of action classification of venlafaxine (Efexor) being an Serotonin Noradrenalin Reuptake Inhibitor (SNRI), although acting as an Selective Serotonin Reuptake Inhibitor (SSRI) in doses up to 150 mg, likely to be disregarded as the SSRI Paroxetine’s (Seroxat) has the highest Affinity and Potency Kd to noradrenalin of any SSRI, SNRI studied?
4 - Can a drugs classification be defined by a catchy marketing tool or will the acronym SNRI be overruled by the scientific facts?
5 – Has the unprecedented media coverage and in particular the BBC’s Panorama issued Yellow Cards damaged the integrity of the MHRA, the system and the case dependant adverse events report evidence?
http://the-uk-seroxat-litigation-chronicles.blogspot.com/2010/10/is-seroxat-group-action-litigation.html
“A product is defective if, at the time of circulation, it is not as "safe as persons generally are entitled to expect," taking account of a number of factors including any instructions or warnings provided with the product and the manner in which it has been marketed.”
In proving a case of a “defective product” the only need is to show the product – in this case GlaxoSmithKline’s (GSK) drug Seroxat (Seroxat UK, Paxil USA) - was not up to consumers’ expectations.However, lead Lawyer Mark Harvey of Hugh James Solicitors, Cardiff has chosen to include a Defining Issue stipulation that any adverse effects and discontinuation, withdrawal difficulties suffered by the Seroxat “user” has to be
“to a greater extent than all other Selective Serotonin Re-uptake Inhibitors (SSRIs)”
HM Courts Service: Seroxat Group Litigation Order no: 68.
The report of the Committee on Safety of Medicines (CSM), Expert Working Group (EWG) on SSRI Antidepressants, published December 2004, found all drugs in the class lacking in safety, efficacy and causing discontinuation problems in up to 80% of consumers.
It’s unclear why the “stipulation” has been included, as The CSM Expert Working Group report on all SSRI Antidepressants effectively proved the Group Action litigants case against GSK by finding their product Seroxat not being as "safe as persons generally are entitled to expect,".
December 2004, Seroxat Group Action Litigation case proved and won -
baring lead lawyer Mark Harvey’s inclusion of the apparently unnecessary and possibly untenable Defining Issue “stipulation”.
To prove the Seroxat Group Action by justifying the included “stipulation” raises the need to examine criteria that differentiate the drugs in the SSRI, SNRI class within the restricted Defining Issue of discontinuation, withdrawal and drug classification.
This depends on the two theories of what causes discontinuation and withdrawal and the issues of selectivity nature, affinity and potency; dose related drug action classification; definition by acronym classification; and external evidence.
All interrelate, and other than the issue of selectivity nature, affinity and potency, focus on two drugs in the class the SSRI paroxetine (Seroxat) and SNRI venlafaxine (Wyeth, Efexor UK, Effexor USA).
The CSM EWG into SSRI Antidepressants used pharmacological characteristics and the 1999 Tatsumi et al study to compare Half-life and the Potency and Affinity of the drugs on the central nervous system neurotransmitters. Finding all drugs have binding affinities to different monoamine transporters, primary effects on different receptors and cause secondary changes in receptor numbers and receptor function at the synapse.
1 - The issue of selectivity nature, affinity and potency is the most complicated – defining whether Seroxat is worse than any other drug in the class by comparing drugs with different intrinsic values that despite their acronym name classification titles i.e. SSRI, SNRI etc - are not “pharmacologically “clean”” or defined in action of selectivity “to the Serotonin system”, all also affecting to varying degrees noradrenalin and dopamine. This aspect is covered in more detail here.
The Tatsumi et al study results are valued using Kd or dissociated constant – as explained on the table the lower the Kd the higher the affinity to the transporter.
Affinity Kd ratings show –
Paroxetine (Seroxat) has the highest affinity to Serotonin at 0.1 - just point 0.2 higher that Sertraline (Pfizer, Lustral UK, Zoloft USA) the second highest at 0.3.
Potency findings published by CSM, EWG are not clear because they have not stated whether they are rating Potency on the Affinity to Serotonin alone or Serotonin (5HT), Noradrenalin (NA) and dopamine (DA).
Potency rating show –
Paroxetine (Seroxat) is the “most potent” with the “lowest selectivity” and Sertraline (Lustral) the “second most potent”.
However, when comparing the Affinity and Potency with other drugs in the class - that all to varying degrees effect 5HT, NA and DA and as Paroxetine (Seroxat) is the least selective and only has a negligible 0.2 higher Affinity to Serotonin than Sertraline (Lustral), total Affinity and Potency Kd values to 5HT, NA and DA could be used to assess this point.
Combined Kd Affinity and Potency values to Serotonin (5HT), Noradrenalin (NA) and Dopamine (DA) show –
Sertraline (Lustral) has the highest combined Affinity and Potency with a Kd 445.3 and the least selective Paroxetine (Seroxat) is second highest with a combined Kd of 530.1.
2 - The two theories of what causes discontinuation and withdrawal is explained by Dr David Healy in the “HALTING SSRIs” document, one theory is the shorter half-life of paroxetine (Seroxat) and venlafaxine (Efexor) makes these drugs more problematic, the second theory is regarding the potency of paroxetine and venlafaxine. This aspect is covered in more detail here.
If according to the first theory - which includes a switch to fluoxetine (Ely Lilly Prozac UK and USA) Half-life 1 to 4 days - the cause of discontinuation and withdrawal is dependant on the shortness of Half-life - venlafaxine (Efexor) has the shortest Half-life of 5 hours - paroxetine (Seroxat) is considerably longer at 20 hours.
The second theory - which includes a switch to citalopram (Lundbeck, Cipramil, Celexa) Kd 1.2 - with regard paroxetine (Seroxat) and venlafaxine (Efexor) being “relatively more potent serotonin reuptake inhibitors” is possibly itself called into question by the findings of the CSM, EWG and Tatsumi et al study as venlafaxine has a Kd value of 152 making it, other than mirtazapine, the least “potent serotonin reuptake inhibitor” of the drugs studied.
This possibly places the whole onus of discontinuation and withdrawal problems inherent with all drugs in the SSRI, SNRI class back on a drugs Half-life as citalopram’s Half-life at 36 hours, is longer than both paroxetine (Seroxat) and venlafaxine (Efexor) – and would possibly benefit some as with the fluoxetine switch.
3 - The dose related drug action classification issue, Wyeth are the only manufacturer of those drugs studied to have specified that their drug works on more than one neurotransmitter, however it is the opinion of Dr David Healy in the “HALTING SSRIs” document and the MHRA that although Venlafaxine is named by the acronym SNRI it’s mode of action is that of an SSRI up to doses of 150 mg, over this it has an additional mode of action to become a serotonin and noradrenalin reuptake inhibitor. This aspect is covered in more detail here
4 - The drug definition by acronym classification title by definition the difference between an SSRI and an SNRI should be dependant on selectivity and potency of action i.e. to serotonin or noradrenalin. In the case of the SSRI, SNRI drug class no drug is “selective” to one monoamine transporter, all drugs effect serotonin and noradrenalin, paroxetine (Seroxat) with Kd of 40 to the noradrenalin transporter has a considerably higher affinity than venlafaxine at a NA of Kd 9400. This aspect is covered in more detail here.
5 - The issue of external evidence, as covered briefly here, is dependant on the MHRA, Yellow Card Scheme adverse drug reports and media coverage that has influenced those reports. The MHRA has received considerably more adverse event reports for paroxetine (Seroxat) than any other drug in the class, however, the December 2004 CSM). EWG Report drew attention to the influence of the media coverage and a number of obviously duplicated reports made with regard paroxetine (Seroxat) and it has been noted that BBC Panorama published and issued it’s own Yellow Cards that were accepted by the MHRA.
I will return to the influence of media coverage, the BBC, Panorama, UK Government officials and departments, the Seroxat User Group.org and Hugh James Solicitors in more depth in future posts - but the media coverage has had a profound influence on this aspect, as the Richard M Martin, Margaret May, and David Gunnell, Department of Social Medicine, University of Bristol study “Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001–2004” shows.
Is the UK Seroxat Group Action Litigation, Order No:68 compromised by Lead Lawyer of Hugh James, Cardiff, Mark Harvey’s included Defining Issue “stipulation”?
1 - Does an Affinity and Potency to serotonin of Kd 0.2 higher than Sertraline (Lustral) make Paroxetine (Seroxat) the worst drug in the class …. or does the highest combined Affinity and Potency Kd to serotonin, noradrenalin and dopamine make Sertraline (Lustral) a worse drug than the least selective Paroxetine (Seroxat)?
2 - If the theory is that discontinuation and withdrawal is caused by the drugs short Half-life …. does SNRI venlafaxine’s (Efexor) half-life of 5 hours make it more difficult to withdraw from than the SSRI Paroxetine’s (Seroxat)?In proving a case of a “defective product” the only need is to show the product – in this case GlaxoSmithKline’s (GSK) drug Seroxat (Seroxat UK, Paxil USA) - was not up to consumers’ expectations.
3 - Is Wyeth’s honest mode of action classification of venlafaxine (Efexor) being an Serotonin Noradrenalin Reuptake Inhibitor (SNRI), although acting as an Selective Serotonin Reuptake Inhibitor (SSRI) in doses up to 150 mg, likely to be disregarded as the SSRI Paroxetine’s (Seroxat) has the highest Affinity and Potency Kd to noradrenalin of any SSRI, SNRI studied?
4 - Can a drugs classification be defined by a catchy marketing tool or will the acronym SNRI be overruled by the scientific facts?
5 – Has the unprecedented media coverage and in particular the BBC’s Panorama issued Yellow Cards damaged the integrity of the MHRA, the system and the case dependant adverse events report evidence?
Seroxat - Paxil NOT habit forming says Paxilprogress founder Darcy Baston
Darcy Baston of Paxilprogress said "I believe that Paxil is not habit forming"
Hereʼs why: for a drug to be labelled habit forming, you have
to demonstrate a drug seeking behavior often at the expense
of rationality, safety, and economic feasibility. This means
you have to be highly desiring of the drug for the sake of
having the drug. This isnʼt quite the case with Paxil.
see
http://www.paxilprogress.org/pdf/Paxil-Withdrawal-Guide-2005.pdf
Hereʼs why: for a drug to be labelled habit forming, you have
to demonstrate a drug seeking behavior often at the expense
of rationality, safety, and economic feasibility. This means
you have to be highly desiring of the drug for the sake of
having the drug. This isnʼt quite the case with Paxil.
see
http://www.paxilprogress.org/pdf/Paxil-Withdrawal-Guide-2005.pdf
Sunday, 17 October 2010
Seroxat Spitzer suit - part of industry wide agenda
Kevin Scotcher, an analyst at SG Securities, said the attorney general has a "much bigger agenda". Mr Scotcher said: "The question is, 'are consumers and doctors in possession of sufficient knowledge?' GSK pays for trials and has control over whether they are published or not. These trials are then used to sell a drug. His lawsuit is exploring something that will lead him to address conflicts of interests across the spectrum. The FDA is financed by the drug industry, for instance."
The Spitzer case will be examined to see if it sets a legal precedent - and GSK's decision to publish the trials will spark a debate over whether it, too, raises the ethical bar on publication.
http://webcache.googleusercontent.com/search?q=cache:hAQY4DjCquEJ:www.independent.co.uk/life-style/health-and-families/health-news/gsk-fights-back-in-battle-with-spitzer-over-seroxat-731788.html+GSK+fights+Seroxat+claims&cd=1&hl=en&ct=clnk&gl=uk
extracted from -
GSK fights back in battle with Spitzer over Seroxat
http://www.independent.co.uk/life-style/health-and-families/health-news/gsk-fights-back-in-battle-with-spitzer-over-seroxat-731788.html
The Spitzer case will be examined to see if it sets a legal precedent - and GSK's decision to publish the trials will spark a debate over whether it, too, raises the ethical bar on publication.
http://webcache.googleusercontent.com/search?q=cache:hAQY4DjCquEJ:www.independent.co.uk/life-style/health-and-families/health-news/gsk-fights-back-in-battle-with-spitzer-over-seroxat-731788.html+GSK+fights+Seroxat+claims&cd=1&hl=en&ct=clnk&gl=uk
extracted from -
GSK fights back in battle with Spitzer over Seroxat
http://www.independent.co.uk/life-style/health-and-families/health-news/gsk-fights-back-in-battle-with-spitzer-over-seroxat-731788.html
£50 million pounds was spent on Benzodiazepine legal aid - yet patients got nothing in that SCAM
http://www.publications.parliament.uk/pa/cm199899/cmselect/cmhealth/549/99072723.htm
In 1993-94 the Benzodiazepine Litigation ended owing to the withdrawal of Legal Aid Board funding. Over £50 million pounds was spent on legal aid and by the drug companies. Since this event the number of prescriptions for all Sedative/Hypnotic drugs has increased by several per cent overall, and that for Valium has increased by 15 per cent (1994-97). The prescribing of the new Sedative/Hypnotic drugs Zolpidem and Zopiclone, which act on the Benzodiazepine receptors has risen dramatically and is now about two million per year. It is very significant that the number of adverse reactions (No/yr/106 pres.) reported for these drugs is very much greater (x100) than for any of the Benzodiazepines. This coincides with many reports to support groups of dependency on these drugs. It appears that the lessons of history have not been learnt and there is an additional dependency epidemic in the making.
In 1993-94 the Benzodiazepine Litigation ended owing to the withdrawal of Legal Aid Board funding. Over £50 million pounds was spent on legal aid and by the drug companies. Since this event the number of prescriptions for all Sedative/Hypnotic drugs has increased by several per cent overall, and that for Valium has increased by 15 per cent (1994-97). The prescribing of the new Sedative/Hypnotic drugs Zolpidem and Zopiclone, which act on the Benzodiazepine receptors has risen dramatically and is now about two million per year. It is very significant that the number of adverse reactions (No/yr/106 pres.) reported for these drugs is very much greater (x100) than for any of the Benzodiazepines. This coincides with many reports to support groups of dependency on these drugs. It appears that the lessons of history have not been learnt and there is an additional dependency epidemic in the making.
Mark Harvey's group calimed 10,000 yet served 314 Seroxat writs - who keeps the public funded legal aid?
http://209.85.229.132/search?q=cache:HVY-Qp_p-YAJ:www.fiercepharma.com/story/uk-patients-sue-paxil-withdrawal/2008-01-09+harvey+seroxat&cd=14&hl=en&ct=clnk
. It was the first antidepressant to be slapped with a suicide-risk warning. It's drawn fire--and lawsuits--from U.S. patients who say they went into withdrawal when trying to quit treatment. Now, a group of UK patients are suing GlaxoSmithKline for the same withdrawal problems, seeking up to $98,000 per patient, or $31 million-plus with the 314 patients participating so far. Of course, it's not simply the monetary damages that could hurt, but the attendant publicity, which might turn off potential patients
Hugh James dropped 97% clients who should contact SRA Fraud and Confidential Intelligence Bureau
Fraud and Confidential Intelligence Bureau is dedicated to gathering information and intelligence, operating in accordance with the National Intelligence Model.
http://www.sra.org.uk/solicitors/scams/fraud-dishonesty.page
http://www.sra.org.uk/solicitors/scams/fraud-dishonesty.page
BBC Panorama / Shelley Jofre KNOWINGLY put lives at risk to support Hugh James Seroxat only litigation
2.30 in Jofre says - ” read a little bit in news paper about patients complaints” year 2000 about ” Seroxat difficult to withdraw from” .. Jofre found it intriguing Jofre had only just started working on Panorama at that stage
3.30 in ” Jofre calls SSRI’s “SELECTIVE Serotonin Reuptake Inhibitors”
4.14 Jofre knew little of how the pharmcutical industry worked
4 .30 in Ed says - lets look at antidepressant story
4 45 Jofre says although problems with whole class of antidepressants we (bbc) decided to concentrate on Seroxat Why we narrowed down on Seroxat 1 because it was made by GSK 2 all the drugs in class cause suicidal thinking on dose change 3 Seroxat had a unique problem of withdrawal BECAUSE IT WAS LONGER ACTING … we decided to focus research into this drug
6.00 in - 40 min Panorama film took Shelley Jofre 8 months to make
6.10 in - It’s not something you do lightly WE WERE TAKING ON the worlds second largest drug company
7.30 We were talking to the lawyer the whole way through production
9.30 in - Jofre says “we took a punt” on Dr David Healy
Seroxat withdrawal freefall - how did they get off - expose legalaid fraud - all SSRI/SNRI not just Seroxat
www.ahrp.org/COI/PaxilDeclineUK.pdf -
Chart 5 demonstrates the immense value to Society of free and independent Public Service
Broadcasting and Internet communication. This combination has triggered the growth of
awareness of SSRI danger. It has united the many thousands of victims of SSRIs across the
world with some professionals who have laboured so long in a cause for saving lives, seeking justice and exposing dysfunctional drug regulation. Chart 5 shows that the tide has turned in the UK. Great encouragement should be taken from this life saving victory. However efforts must continue both to expose the known risks of paroxetine (Seroxat, Paxil) and all the other ill validated SSRIs and to call for the establishment an effective independent Drug Safety Regulator in every country, the absence of which is the root cause of this ongoing officially supported tragedy.
Graham Aldred 17 May 2004
Chart 5 demonstrates the immense value to Society of free and independent Public Service
Broadcasting and Internet communication. This combination has triggered the growth of
awareness of SSRI danger. It has united the many thousands of victims of SSRIs across the
world with some professionals who have laboured so long in a cause for saving lives, seeking justice and exposing dysfunctional drug regulation. Chart 5 shows that the tide has turned in the UK. Great encouragement should be taken from this life saving victory. However efforts must continue both to expose the known risks of paroxetine (Seroxat, Paxil) and all the other ill validated SSRIs and to call for the establishment an effective independent Drug Safety Regulator in every country, the absence of which is the root cause of this ongoing officially supported tragedy.
Graham Aldred 17 May 2004
Saturday, 16 October 2010
Fiddaman visitor statistics rigged - the evidence is clear
Fiddaman's page views rigged - most NOT interested in Seroxat
GSK NOT concerned about Seroxat sales - because millions easily withdrew
SSRI, SNRI - 2009 Annual Total Prescription Increases Hit Record High - 2.54 million
http://tuesday1st.blogspot.com/
Friday, 15 October 2010
Seroxat suit comprises only 314 clients © 2009 FierceMarkets
Seroxat TRUTH - suit comprises only 314 clients © 2009 FierceMarkets
Seroxat suit comprises only 314 clients © 2009 FierceMarkets
http://209.85.229.132/search?q=cache:HVY-Qp_p-YAJ:www.fiercepharma.com/story/uk-patients-sue-paxil-withdrawal/2008-01-09+harvey+seroxat&cd=14&hl=en&ct=clnk
Poor Paxil. It was the first antidepressant to be slapped with a suicide-risk warning. It's drawn fire--and lawsuits--from U.S. patients who say they went into withdrawal when trying to quit treatment. Now, a group of UK patients are suing GlaxoSmithKline for the same withdrawal problems, seeking up to $98,000 per patient, or $31 million-plus with the 314 patients participating so far. Of course, it's not simply the monetary damages that could hurt, but the attendant publicity, which might turn off potential patients.
Sold as Seroxat in the UK, the drug is "defective" under Britain's 1987 Consumer Protection Act--or so says the patients' attorney, Mark Harvey of the law firm Hugh James. A few of his clients have not been able to stop taking Seroxat because of their withdrawal symptoms, he says. When they began treatment, not only was there no warning of withdrawal problems on the drug's label, but it specifically stated that the drug was not addictive.
Harvey has been working on this suit since at least 2004, when it first became fashionable to sue Glaxo for Paxil/Seroxat-related woes. The drug was banned in the UK for kids under 18 in 2003; since then, lawsuits over paroxetine's side effects have flown on both sides of the Atlantic.Read more: http://209.85.229.132/search?q=cache:HVY-Qp_p-YAJ:www.fiercepharma.com/story/uk-patients-sue-paxil-withdrawal/2008-01-09+harvey+seroxat&cd=14&hl=en&ct=clnk
Seroxat suit comprises only 314 clients © 2009 FierceMarkets
http://209.85.229.132/search?q=cache:HVY-Qp_p-YAJ:www.fiercepharma.com/story/uk-patients-sue-paxil-withdrawal/2008-01-09+harvey+seroxat&cd=14&hl=en&ct=clnk
Poor Paxil. It was the first antidepressant to be slapped with a suicide-risk warning. It's drawn fire--and lawsuits--from U.S. patients who say they went into withdrawal when trying to quit treatment. Now, a group of UK patients are suing GlaxoSmithKline for the same withdrawal problems, seeking up to $98,000 per patient, or $31 million-plus with the 314 patients participating so far. Of course, it's not simply the monetary damages that could hurt, but the attendant publicity, which might turn off potential patients.
Sold as Seroxat in the UK, the drug is "defective" under Britain's 1987 Consumer Protection Act--or so says the patients' attorney, Mark Harvey of the law firm Hugh James. A few of his clients have not been able to stop taking Seroxat because of their withdrawal symptoms, he says. When they began treatment, not only was there no warning of withdrawal problems on the drug's label, but it specifically stated that the drug was not addictive.
Harvey has been working on this suit since at least 2004, when it first became fashionable to sue Glaxo for Paxil/Seroxat-related woes. The drug was banned in the UK for kids under 18 in 2003; since then, lawsuits over paroxetine's side effects have flown on both sides of the Atlantic.Read more: http://209.85.229.132/search?q=cache:HVY-Qp_p-YAJ:www.fiercepharma.com/story/uk-patients-sue-paxil-withdrawal/2008-01-09+harvey+seroxat&cd=14&hl=en&ct=clnk
"are the press looking for seroxat clients" - top keyword search
October 15, 2010
PM Google are the press looking for seroxat clients
http://bobfiddaman.blogspot.com/2010/10/media-publicity-impact-on-prescribing.html
PM Google are the press looking for seroxat clients
http://bobfiddaman.blogspot.com/2010/10/media-publicity-impact-on-prescribing.html
GlaxoSmithKline's Lawyers - UK SEROXAT LITIGATION AND THE UK PRESS.- most viewed post
When I tapered off Paxil I used an oral syringe. I 'came down' by half a mg per week and it took me 18 months to taper down from 40mg per day to 22mg per day. That is NOT a discontinuation, that IS a withdrawal. Paxil IS addictive, there are thousands of stories of people suffering because they cannot taper off this drug.
After 18 months I went cold turkey. It took me 3 months to get passed the zaps, profuse sweating, anger outbursts, suicidal thoughts, craving (temptation to go back on Paxil) plus a whole host of other side effects.
There are over 10,000 stories online from patients who have suffered withdrawal symptoms at the hands of Paxil. To suggest that antidepressants are not addictive is basically sticking your middle finger up to those that have... and still are suffering trying to taper off this drug.
http://neighbors.denverpost.com/viewtopic.php?f=16&t=9437847&p=221585
After 18 months I went cold turkey. It took me 3 months to get passed the zaps, profuse sweating, anger outbursts, suicidal thoughts, craving (temptation to go back on Paxil) plus a whole host of other side effects.
There are over 10,000 stories online from patients who have suffered withdrawal symptoms at the hands of Paxil. To suggest that antidepressants are not addictive is basically sticking your middle finger up to those that have... and still are suffering trying to taper off this drug.
http://neighbors.denverpost.com/viewtopic.php?f=16&t=9437847&p=221585
Thursday, 14 October 2010
Seroxat - Paxil protest photographs of Rob Robinson's non event
Seroxat/Paxil - sales in freefall HOW DID THEY WITHDRAW?
Seroxat Panorama watched by 4.4 million - produced only 1,374 e-mails !
An estimated 4.4m people recently watched “Secrets of Seroxat” (Panorama, BBC-TV), a 50-minute programme about paroxetine, an SSRI antidepressant for which UK general practitioners wrote an estimated 4.7m prescriptions in 2001. The programme attracted a record response, including some 65,000 telephone calls, 124,000 website hits, and 1,374 emails.We systematically analysed the contents of these emails, and in this paper consider how they might help clinicians and their patients, as well as providing an indispensable element in pharmacovigilance and post-marketing drug surveillance.
http://www.motkur.no/paroxetine.pdf
from
Paroxetine, Panorama and user reporting of
ADRs: Consumer intelligence matters in
clinical practice and post-marketing drug
surveillance
Charles Medawar a,∗, Andrew Herxheimer b, Andrew Bell c and Shelley Jofre c
a Social Audit Ltd., London, UK
bDIPEx Project, Department of Primary Health Care, University of Oxford, Oxford, UK
c British Broadcasting Corporation (BBC), London, UK
http://www.motkur.no/paroxetine.pdf
from
Paroxetine, Panorama and user reporting of
ADRs: Consumer intelligence matters in
clinical practice and post-marketing drug
surveillance
Charles Medawar a,∗, Andrew Herxheimer b, Andrew Bell c and Shelley Jofre c
a Social Audit Ltd., London, UK
bDIPEx Project, Department of Primary Health Care, University of Oxford, Oxford, UK
c British Broadcasting Corporation (BBC), London, UK
Subscribe to:
Posts (Atom)





